The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase III, international, multicentre, double-blind, dose increment, parallel-arm, randomised controlled trial of duloxetine versus pregabalin for opioid-unresponsive neuropathic cancer pain.
 
Hiromichi Matsuoka
Honoraria - Daiichi Sankyo Pharmaceutical; Eisai; Hisamitsu Pharmaceutical; Tsumura & Co.
Speakers' Bureau - Eisai; Hisamitsu Pharmaceutical; Shionogi; Tsumura & Co.
 
Katherine Clark
No Relationships to Disclose
 
Belinda Fazekas
No Relationships to Disclose
 
Shunsuke Oyamada
Honoraria - Chugai Pharma
 
Linda Brown
No Relationships to Disclose
 
Hiroto Ishiki
Speakers' Bureau - Daiichi Sankyo/Lilly; EA Pharma; Hisamitsu Pharmaceutical; Mundipharma; Pfizer; Shionogi
 
Yoshinobu Matsuda
Honoraria - Chugai Pharma; Fujimoto; Hisamitsu Pharmaceutical; Nippon Boehringer Ingelheim; Takeda
 
Hideaki Hasuo
No Relationships to Disclose
 
Keisuke Ariyoshi
No Relationships to Disclose
 
Jessica Lee
No Relationships to Disclose
 
Brian H. Le
No Relationships to Disclose
 
Noriko Fujiwara
Honoraria - Chugai Pharma; Mitsubishi Tanabe Pharma
 
Tempei Miyaji
Honoraria - AYUMI; Pfizer; Welby
Research Funding - 3H Medi Solution (Inst); A2 Healthcare (Inst); AC Medical (Inst); FMD K&L Japan (Inst); intellim (Inst); Japan Media Corporation (Inst); Japan Tobacco Inc (Inst); Medidata Solutions, Inc (Inst); Medrio (Inst); New Age Trading (Inst); Nipro Corporation (Inst); NOBORI Ltd. (Inst); Ono Pharmaceutical (Inst); Welby (Inst)
 
Meera Ruth Agar
No Relationships to Disclose
 
Takuhiro Yamaguchi
Stock and Other Ownership Interests - STATCOM
Consulting or Advisory Role - 3H Clinical Trial; Chugai Pharma; DAIICHI SANKYO COMPANY, LIMITED.; Eisai; EP Croit Co.; Incyte; Japan Tobacco Inc; Kowa; Ono Pharmaceutical; Otsuka; Seikagaku; Sonire Therapeutics
Speakers' Bureau - AstraZeneca; Daiichi Sankyo; Mebix; Takeda
Research Funding - 3H Clinical Trial (Inst); 3H Medi Solution (Inst); A2 Healthcare (Inst); AC Medical (Inst); ClinChoice (Inst); Eisai (Inst); Facet Biotech (Inst); Hemp Kitchen (Inst); intellim (Inst); Japan Media Corporation (Inst); Japan Tobacco Inc (Inst); Kyowa Kirin Co., Ltd.; Medidata Solutions, Inc (Inst); Medrio (Inst); NIPRO CORPORATION (Inst); Nobori Ltd. (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Puravida Technologies (Inst); Senju Pharmaceutical (Inst); Welby (Inst)
 
Eriko Satomi
Honoraria - Abbott Japan (I); Bayer (I); Boehringer Ingelheim (I); Boston Scientific (I); Bristol-Myers Squibb (I); Chugai Pharma; Daiichi Sankyo; Daiichi Sankyo (I); Eisai; Eisai (I); Fukuda Denshi (I); Hisamitsu Pharmaceutical; Johnson & Johnson (I); Kyowa Kirin International; Medtronic (I); Medtronic (I); Mylan; Otsuka (I); Pfizer; Pfizer (I); Shionogi; St. Jude Medical (I); TERUMO; Terumo (I); TOA EIYO (I); Tsumura & Co.; Tsumura & Co.
Consulting or Advisory Role - Japan Lifeline (I)
Research Funding - Biotronik International (I)
 
Satoru Iwase
No Relationships to Disclose
 
Jane Phillips
No Relationships to Disclose
 
Atsuko Koyama
No Relationships to Disclose
 
David Christopher Currow
No Relationships to Disclose